Home » Interviews » INTERVIEW: SkinBioTherapeutics Plc Getting the Attention of the ‘Big Boys’
SkinBioTherapeutics plc

INTERVIEW: SkinBioTherapeutics Plc Getting the Attention of the ‘Big Boys’

SkinBioTherapeutic Plc (LON:SBTX) CEO Dr Cath O’Neill explains to DirectorsTalk how the company is now being looked at by a Global Giant. Cath explains what the MTA agreement means and what this means for the company.

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain. The compay platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. STBX received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix Health Plc (LON:OPTI).